KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Arbutus Biopharma (ABUS) over the last 12 years, with Sep 2025 value amounting to $11,000.

  • Arbutus Biopharma's Depreciation & Amortization (CF) fell 96.73% to $11,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $688,000, marking a year-over-year decrease of 51.41%. This contributed to the annual value of $1.4 million for FY2024, which is 0.28% down from last year.
  • Arbutus Biopharma's Depreciation & Amortization (CF) amounted to $11,000 in Q3 2025, which was down 0.00% from $11,000 recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Depreciation & Amortization (CF) peaked at $474,000 during Q4 2021, and registered a low of $11,000 during Q2 2025.
  • For the 3-year period, Arbutus Biopharma's Depreciation & Amortization (CF) averaged around $271,556, with its median value being $336,000 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first increased by 7.58% in 2023, then crashed by 96.91% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Depreciation & Amortization (CF) (Quarterly) stood at $474,000 in 2021, then declined by 23.27% to $343,000 in 2022, then rose by 7.58% to $369,000 in 2023, then fell by 8.94% to $336,000 in 2024, then tumbled by 96.73% to $11,000 in 2025.
  • Its last three reported values are $11,000 in Q3 2025, $11,000 for Q2 2025, and $330,000 during Q1 2025.